Advertisement
Advertisement
ALT
Altimmune, Inc. Common Stock
3.02
USDSponsored
-0.06
-1.95%
May 13, 15:58 UTC -4
Closed
Pre-Market
3.02
0.00
+0.17%
ALT Earnings Reports
Positive Surprise Ratio
ALT beat 23 of 33 last estimates.
70%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$717.00
/-$0.24
Implied change from Q1 26 (Revenue/ EPS)
--
/+33.33%
Implied change from Q2 25 (Revenue/ EPS)
-85.66%
/-11.11%
Altimmune, Inc. Common Stock earnings per share and revenue
On May 13, 2026, ALT reported earnings of -0.18 USD per share (EPS) for Q1 26, beating the estimate of -0.24 USD, resulting in a 27.18% surprise. Revenue reached --, compared to an expected 717, with a -100.00% difference. The market reacted with a -1.95% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -0.24 USD, with revenue projected to reach 717 USD, implying an increase of 33.33% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Relmada Therapeutics, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.19
Actual
-$0.22
Surprise
-10.61%
Aquestive Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.13
Actual
-$0.07
Surprise
+49.96%
Prelude Therapeutics Incorporated
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.13
Surprise
+48.68%
Unicycive Therapeutics, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.51
Actual
-$0.54
Surprise
-4.49%
Karyopharm Therapeutics Inc.
Report Date
May 14, 2026 For Q1 26
Estimate
-$1.45
Actual
-$1.24
Surprise
+14.90%
Journey Medical Corporation Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-1.14%
Verrica Pharmaceuticals Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.38
Actual
-$0.41
Surprise
-5.92%
PolyPid Ltd. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.81%
Takeda Pharmaceutical Company Limited - ADR
Report Date
May 13, 2026 For Q4 26
Estimate
-$24.25
Actual
$44.19
Surprise
+282.20%
Talphera, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.04
Surprise
+43.98%
FAQ
What were Altimmune, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Altimmune, Inc. Common Stock reported EPS of -$0.18, beating estimates by 27.18%, and revenue of $0.00, -100% below expectations.
How did the market react to Altimmune, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -1.95%, changed from $3.08 before the earnings release to $3.02 the day after.
When is Altimmune, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Altimmune, Inc. Common Stock's next earnings report?
Based on 9
analysts, Altimmune, Inc. Common Stock is expected to report EPS of -$0.24 and revenue of $717.00 for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement